<DOC>
	<DOCNO>NCT00852956</DOCNO>
	<brief_summary>This phase I , randomize , two-arm , double-blind , placebo-controlled , sequential study 50 healthy female subject . The study comprise three treatment period total 4 week treatment duration : Period I 1 week ( Days 1-7 ) administration betahistine daily ( three time per day ; 144 mg/day total ) match placebo . Period II 1 week ( Days 8-14 ) titration olanzapine daily ( 2.5 10 mg ) continuation betahistine match placebo administration ( daily ; three time per day ) Period III 2 week ( Days 15-28 ) continue co-administration betahistine/matching placebo , three time per day , olanzapine daily ( 7.5 10 mg/day )</brief_summary>
	<brief_title>Evaluation Safety , Drug-Drug Interactions Pharmacokinetic Profiles Co-Administration Betahistine With Olanzapine Healthy Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Betahistine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>1 . Healthy female subject 18 45 year age . 2 . Signed write informed consent . 3 . Willing able comply study procedure ( include stay overnight research facility require period PK sampling ) . 4 . Regular menstrual period . 5 . All subject nonlactating , negative urine pregnancy test result , plan become pregnant study , must practice willing continue practice appropriate birth control ( implant , injectables , oral contraceptive , intrauterine contraceptive device , sexual abstinence , tubal ligation , vasectomized partner ) entire study duration . 6 . Has stable treatment regimen follow medication minimum 90 day prior screen : Hormone replacement therapy ; Oral contraceptive . 1 . Has abnormal body composition , either overweight obesity ( BMI &gt; 27 Kg/m2 ) undernourishment ( BMI &lt; 18.5 Kg/m2 ) . 2 . Has significant body weight loss &gt; 4 kg 90 day prior screen . 3 . Pregnancy lactation . 4 . Has recently start smoke cessation program . 5 . Has know sensitivity betahistine olanzapine . 6 . Having first degree relative diabetes . 7 . Personal history gestational diabetes . 8 . Subjects diagnose polycystic ovary disease . 9 . Has clinically significant history presence follow condition : Active past history cardiovascular cerebrovascular disease include unstable angina , myocardial infarction , transient ischemic attacks/stroke , clinically significant arrhythmia , congestive heart failure , cardiac valve abnormality Diabetes mellitus ( type 1 2 ) Fasting blood glucose level &gt; 100 mg/dL HBA1c &gt; 6.0 % screening . Renal insufficiency define serum creatinine &gt; 1.5 mg/dL ( 133 Âµmol/L ) screen Malignant disease within 5 year screen Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2 ULN Thyroidstimulating hormone ( TSH ) outside normal range Plans surgery ( elective otherwise ) course study Has hypertension ( sit blood pressure &gt; 140/90 mmHg screen randomization ) , Has hyperlipidemia ( triglycerides [ TG ] &gt; 200 mg/dL lowdensity lipoprotein cholesterol [ LDLC ] &gt; 190 mg/dL ) , History asthma History peptic ulcer History HIV , Hepatitis B , Hepatitis C Has clinical laboratory test value ( chemistry , hematology , metabolic urinalysis ) judge clinically significant investigator Has physical examination electrocardiogram ( ECG ) significant abnormality , judge investigator Currently abuse drug alcohol history abuse investigator 's opinion could cause subject noncompliant study procedure Has psychiatric neurological disorder require chronic medication ( e.g. , antidepressant , antipsychotic anti anxiety agent ) . Chronic need use antihistamine 10 . Has treat past 60 day , currently treat , expect require undergo treatment medication period 3 day ( exception antibiotic treatment period le 7 day ) . 11 . Has receive investigational drug within 90 day prior screen . 12 . Is immediate family member personnel directly affiliate study investigative site , personally directly affiliate study investigative site ; employed OBEcure Ltd .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Betahistine</keyword>
	<keyword>Olanzapine</keyword>
	<keyword>Safety co-administration Betahistien Olanzapine</keyword>
</DOC>